Semaglutide – 10mg

Semaglutide is a synthetic 31-amino-acid peptide developed as a selective agonist of the glucagon-like peptide-1 (GLP-1) receptor. The peptide is structurally derived from native human GLP-1(7-37) with two amino acid substitutions (Aib at position 8 for DPP-IV resistance, Arg substitution at position 34) and a C18 fatty diacid moiety conjugated via a γGlu-(AEEA)₂ linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly dosing. Semaglutide is one of the most extensively characterized incretin-based research peptides, with published preclinical and clinical research investigating its effects on glycemic endpoints, body composition, gastric emptying, appetite regulation, and cardiometabolic markers across obesity and metabolic disease models. It is FDA-approved as Ozempic® (2017), Wegovy® (2021), and Rybelsus® (2019, oral formulation), and serves as the reference compound for the broader class of long-acting GLP-1 receptor agonists.

Benefits (Research Focus)

• GLP-1 receptor agonism — studied for selective activation of the GLP-1 receptor with downstream insulin and glucagon regulation

• Glycemic control research — investigated for fasting glucose, HbA1c, and insulin sensitivity parameters in T2D models

• Body composition — examined for fat-mass and lean-mass partitioning in DIO and obesity models

• Appetite and gastric pathways — explored for satiety signaling and delayed gastric emptying endpoints

• Long-acting profile — C18 fatty diacid albumin-binding chemistry for extended half-life (~7 days)

What Researchers Look At

• GLP-1 receptor binding affinity, cAMP activation, and β-arrestin recruitment

• Food intake, body weight, and adipose-tissue change in DIO rodent models

• Pancreatic β-cell function and insulinotropic response endpoints

• Gastric emptying time and gastrointestinal transit profiles

• Comparative pharmacology versus tirzepatide, retatrutide, and other incretin analogs

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 10 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Semaglutide

• Synonyms: NN9535; NNC0113-0987

• Class: Selective GLP-1 receptor agonist; long-acting incretin analog (31 amino acids)

• Modification: Lipidated with C18 fatty diacid via γGlu-(AEEA)₂ linker on Lys²⁶ residue; aminoisobutyric acid (Aib) substitution at position 8 for DPP-IV resistance; Arg substitution at position 34

• Formula / M.W.: C₁₈₇H₂₉₁N₄₅O₅₉, ~4113.58 g/mol

• CAS: 910463-68-2

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Semaglutide 10mg VPeptide Canada — December 5, 2025

• Semaglutide 10mg VPeptide Canada — June 15, 2026

• Semaglutide 10mg VPeptide Canada — July 13, 2026